Abstracts tagged "Ankylosing spondylitis (AS) and biomarkers"

Abstract Number: 1655 • 2016 ACR/ARHP Annual Meeting
Plasma microRNA Expression Profiles in Ankylosing Spondylitis Patients
Pilar Font-Ugalde¹, Carlos Perez-Sanchez¹, Chary Lopez-Pedrera¹, M. Carmen Castro-Villegas², Maria Carmen Abalos-Aguilera³, Patricia Ruiz-Limon³, Nuria Barbarroja¹, Ivan Arias de la Rosa³, Rafaela Ortega-Castro¹, Alejandro Escudero-Contreras³, Eduardo Collantes-Estévez¹ and Yolanda Jiménez-Gómez¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain
Background/Purpose: MicroRNAs (miRNAs) are a group of single-stranded non-coding RNAs of 20-25 nucleotides in length that can potentially regulate every aspect of cellular function. Recent…
Abstract Number: 1666 • 2016 ACR/ARHP Annual Meeting
Micrornas Mir-30b-5p, Mir-34a-5p, and Mir-431-3p Are Highly Expressed in the Plasma of Patients with Ankylosing Spondylitis
Abdul Haseeb¹, Tariq M. Haqqi¹ and Marina N. Magrey², ¹Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH, ²Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: The role of miRNAs in immune and inflammatory diseases is increasing exponentially. miRNAs are present in the human plasma in stable form. We proposed…
Abstract Number: 2713 • 2016 ACR/ARHP Annual Meeting
Differentially Expressed Microrna As Candidate Biomarker for Disease Activity in Ankylosing Spondylitis
Marina N. Magrey¹, Abdul Haseeb² and Tariq M Haqqi², ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH
Differentially Expressed MicroRNA as candidate Biomarker for Disease Activity in Ankylosing Spondylitis Background/Purpose: MicroRNAs (miRNAs) have evolved as a novel class of biomarkers We proposed…
Abstract Number: 1252 • 2015 ACR/ARHP Annual Meeting
Serum Biomarkers Associated with Disease Activity and Response to Ustekinumab in Patients with Ankylosing Spondylitis
Bidisha Dasgupta¹, Shannon Telesco², Joachim Sieper³ and Denis Poddubnyy⁴, ¹Janssen Research & Development, LLC., Spring House, PA, ²Janssen R & D, LLC, Spring House, PA, ³University Clinic Benjamin Franklin, Berlin, Germany, ⁴Rheumatology, Charité - Campus Benjamin Franklin, Berlin, Germany
Background/Purpose: A recent POC, open label trial (TOPAS)1 showed efficacy of ustekinumab (a monoclonal antibody against IL12 and IL23p40 in pts with active AS. To identify novel serum…
Abstract Number: 2615 • 2014 ACR/ARHP Annual Meeting
Preliminary Assessment of a Multi-Biomarker Disease Activity Test for Axial Spondyloarthritis
Walter P. Maksymowych¹, Stephanie Wichuk¹, P. Scott Eastman² and Eric H. Sasso³, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Crescendo Bioscience, Inc., South San Francisco, CA, ³Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose There has been limited validation of soluble biomarker measures of disease activity in patients with axial spondyloarthritis (SpA). C-reactive protein (CRP) is most commonly…
Abstract Number: 2601 • 2014 ACR/ARHP Annual Meeting
Serum Biomarkers Associated with Changes in ASDAS and MRI Following Treatment of Ankylosing Spondylitis with Golimumab
Robert D. Inman¹, Xenofon Baraliakos², Kay-Geert A. Hermann³, Jürgen Braun⁴, Atul A. Deodhar⁵, Désirée van der Heijde⁶, Stephen Xu⁷ and Benjamin Hsu⁷, ¹Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ³Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Oregon Health and Sciences University, Portland, OR, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Janssen Research & Development, LLC., Spring House, PA
Background/Purpose Serum biomarkers that can predict subsequent clinical or imaging outcomes would aid decision-making in the management of ankylosing spondylitis (AS). Using data from the…
Abstract Number: 565 • 2012 ACR/ARHP Annual Meeting
Fetuin A: A New Biomarker Related with Syndesmophytes in Patients with Ankylosing Spondylitis
Tugba Tuylu¹, Dilek Solmaz², Ismail Sari², Didem L. Kozaci³, Servet Akar⁴, Necati Gunay³ and Nurullah Akkoc⁵, ¹Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ³Biochemistry, Adnan Menderes University School of Medicine, Aydin, Turkey, ⁴Rheumatology, Dokuz Eylul University School of Medicine Department of Internal Medicine Division of Rheumatology, Izmir, Turkey, ⁵Rheumatology, Dokuz Eylul University School Of Medicine, Department Of Internal Medicine, Division Of Rheumatology, Izmir, Turkey
Background/Purpose: In recent years, there is considerable interest regarding prediction and pathogenesis of syndesmophyte formation. Thus, several studies were conducted in order to identify the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].